Histology and fine structure of the iris and outflow system following latanoprost therapy

被引:15
作者
Grierson, I
Pfeiffer, N
Cracknell, KPB
Appleton, P
机构
[1] Univ Liverpool, Univ Clin Dept, Dept Med, Unit Ophthalmol, Liverpool L69 3GA, Merseyside, England
[2] Univ Mainz Klinikum, Dept Ophthalmol, Mainz, Germany
关键词
eye color change; iris; latanoprost; melanin; morphology; outflow system;
D O I
10.1016/S0039-6257(02)00304-1
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Latanoprost therapy can lead to iris darkening in susceptible individuals, particularly those with hazel eyes. Concerns have been raised about whether latanoprost, and for that matter other prostanoids, may have a harmful effect on the iris. In addition, it is unknown whether latanoprost causes increased pigmentation of the outflow pathways that might eventually lead to blockage and a type of pigmentary glaucoma. The present study summarizes findings from the authors' own laboratories on the effects of latanoprost as seen by light and electron microscopy of the iris and outflow tissues and reviews the as yet limited, relevant literature. The findings support the proposal that latanoprost-induced eye color change is likely to be due to an increased amount of melanin within iris stromal melanocytes rather than any increase in melanocyte numbers, although many aspects of the darkening process remain obscure. No marked pathological changes were found in the latanoprost-treated iris; however, the numbers of specimens examined by us to date are still small (40 specimens in all) and those with latanoprost-induced darkening are even fewer (18). In the authors' experience, pigmentation of the outflow system in latanoprost-treated eyes was no greater than in eyes with primary open-angle glaucoma without prostanoid treatment, but there have been only limited numbers of trabeculectomy specimens examined. Concerns about latanoprost producing meshwork hyperpigmentation and pigmentary glaucoma are discussed.
引用
收藏
页码:S176 / S184
页数:9
相关论文
共 30 条
[1]   Prostaglandin derivates as ocular hypotensive agents [J].
Alm, A .
PROGRESS IN RETINAL AND EYE RESEARCH, 1998, 17 (03) :291-312
[2]   Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States [J].
Alm, A ;
Camras, CB ;
Watson, PG .
SURVEY OF OPHTHALMOLOGY, 1997, 41 :S105-S110
[4]  
BROEKHUYSE RM, 1993, INVEST OPHTH VIS SCI, V34, P698
[5]   PIGMENTARY DISPERSION AND GLAUCOMA - NEW THEORY [J].
CAMPBELL, DG .
ARCHIVES OF OPHTHALMOLOGY, 1979, 97 (09) :1667-1672
[6]   MIB-1 and PC-10 immunostaining for the assessment of proliferative activity in primary acquired melanosis without and with atypia [J].
Chowers, I ;
Livni, N ;
Solomon, A ;
Zajicek, G ;
Frucht-Pery, J ;
Folberg, R ;
Pe'er, J .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1998, 82 (11) :1316-1319
[7]   α-methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro [J].
Drago, F ;
Marino, A ;
La Manna, C .
EXPERIMENTAL EYE RESEARCH, 1999, 68 (01) :85-90
[8]  
Eagle R C Jr, 1988, Trans Am Ophthalmol Soc, V86, P581
[9]   CURRENT CONCEPTS IN PIGMENTARY GLAUCOMA [J].
FARRAR, SM ;
SHIELDS, MB .
SURVEY OF OPHTHALMOLOGY, 1993, 37 (04) :233-252
[10]  
Freddo TF, 1996, MICROSC RES TECHNIQ, V33, P369, DOI 10.1002/(SICI)1097-0029(19960401)33:5<369::AID-JEMT1>3.0.CO